A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer.

ABSTRACT:

Objective

The objective of this study was to assess the effectiveness and safety of CDK4/6 inhibitors in the treatment of hormone receptor-positive (HR+) breast cancer by using meta-analysis.

Methods

To gather comprehensive and reliable data for our analysis, we systematically searched multiple databases for relevant studies. We utilized RevMan5.3 software to perform the meta-analysis.

Results

Following a rigorous screening and evaluation process, we ultimately included a total of 13 studies in our analysis. Our findings showed that compared to endocrine therapy alone, the combination of CDK4/6 inhibitors with endocrine therapy significantly increased both PFS [HR 0.54 (95%CI: 0.50, 0.58), P<0.00001], OS [HR 0.77 (95%CI: 0.50, 0.58), P<0.00001] and ORR [

SUBMITTER: Zhang J 

PROVIDER: S-EPMC11913826 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature